评估骨折风险及骨质疏松症药物的作用：骨密度及其他方面

Assessing fracture risk and effects of osteoporosis drugs: bone mineral density and beyond.

作者信息

Davison K Shawn, Kendler David L, Ammann Patrick, Bauer Douglas C, Dempster David W, Dian Larry, Hanley David A, Harris Steven T, McClung Michael R, Olszynski Wojciech P, Yuen Chui K

机构信息

Department of Medicine, Division of Rheumatology and Immunology, Laval University, Quebec, PQ, Canada.

出版信息

Am J Med. 2009 Nov;122(11):992-7. doi: 10.1016/j.amjmed.2009.05.018.

DOI:10.1016/j.amjmed.2009.05.018

PMID:19854322

Abstract

Although there have been numerous advances in the assessment of bone strength and fracture risk, the majority of these techniques can only be performed in research laboratories, making them largely unavailable to practicing clinicians. Prospective epidemiologic studies have identified risk factors that can be assessed within the clinic and combined with bone mineral density to allow clinicians to better identify untreated individuals at heightened risk for fracture and to make informed treatment decisions based on 10-year absolute fracture risk. This article discusses the assessment of fracture risk in clinical practice, reviews currently and soon-available bone measurement tools, and details the impacts of osteoporosis therapies on fracture risk.

摘要

尽管在骨强度和骨折风险评估方面已经取得了许多进展，但这些技术大多只能在研究实验室中进行，这使得临床医生基本上无法使用。前瞻性流行病学研究已经确定了一些风险因素，这些因素可以在临床环境中进行评估，并与骨密度相结合，使临床医生能够更好地识别未接受治疗但骨折风险较高的个体，并根据10年绝对骨折风险做出明智的治疗决策。本文讨论了临床实践中骨折风险的评估，回顾了当前和即将可用的骨测量工具，并详细介绍了骨质疏松症治疗对骨折风险的影响。